Melissa Poncy
Nurse Practitioner · Denver, CONPI 1376286369
Payments from drug & device makers
Across 45 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$119
- Beigene USA, Inc.$78
- Johnson & Johnson$76
- Incyte Corporation$66
- Merck$61
- Bristol Myers Squibb$57
- plus $562 from 19 others
What the payments were for
- Food & beverage$1,020100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 5 | $119 |
| Beigene USA, Inc. | 3 | $78 |
| Johnson & Johnson | 4 | $76 |
| Incyte Corporation | 3 | $66 |
| Merck | 3 | $61 |
| Bristol Myers Squibb | 2 | $57 |
| Jazz Pharmaceuticals Inc. | 2 | $56 |
| Kyowa Kirin, Inc. | 2 | $52 |
| Karyopharm Therapeutics Inc. | 2 | $43 |
| GSK | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Pfizer | 2 | $38 |
| Sanofi | 1 | $31 |
| Legend Biotech USA Inc. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Sobi, Inc | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $22 |
| Syndax Pharmaceuticals, Inc. | 1 | $21 |
| Novartis | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
How this compares
$1,020 in reported general payments places this provider in the 85th percentile of 1,384 nurse practitioner providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 21 | $1,084 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 48 | $276 |
| Gabapentin | 12 | $119 |
| Levofloxacin | 11 | $109 |
| Acyclovir | 20 | $99 |
| Potassium Chloride | 14 | $67 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Denver
- Christina ProulxDenver$222K
- Jose Diaz LeoDenver$24K
- Lolanda McBrideDenver$20K
- Cori FratelliDenver$15K
- Leslie HindsDenver$9K
- Rebecca AndrieDenver$8K
- Nahid Kuseh Kalani YazdDenver$8K
- Amber Whitton-SmithDenver$7K
- Jacqueline CarboneDenver$7K
- Stephanie WyttenbachDenver$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.